Total Payments
$165,251
2024 Payments
$33,801
Companies
12
Transactions
93
Medicare Patients
1,346
Medicare Billing
$181,565
Payment Breakdown by Category
Consulting$85,100 (51.5%)
Travel$33,534 (20.3%)
Research$27,780 (16.8%)
Other$16,090 (9.7%)
Food & Beverage$2,748 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $85,100 | 26 | 51.5% |
| Travel and Lodging | $33,534 | 16 | 20.3% |
| Unspecified | $27,780 | 17 | 16.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,090 | 13 | 7.9% |
| Honoraria | $3,000 | 1 | 1.8% |
| Food and Beverage | $2,748 | 20 | 1.7% |
Payments by Type
General
$137,471
76 transactions
Research
$27,780
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $91,294 | 59 | $0 (2023) |
| Novo Nordisk AS | $48,572 | 10 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $8,048 | 8 | $0 (2024) |
| GlaxoSmithKline, LLC. | $6,700 | 5 | $0 (2017) |
| Alexion Pharmaceuticals, Inc. | $3,645 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $3,008 | 4 | $0 (2024) |
| ARRAY BIOPHARMA INC | $3,000 | 1 | $0 (2022) |
| VERTEX PHARMACEUTICALS INCORPORATED | $550.00 | 1 | $0 (2018) |
| Edwards Lifesciences Corporation | $186.48 | 1 | $0 (2024) |
| CVRx, Inc. | $161.61 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33,801 | 12 | Novo Nordisk AS ($25,192) |
| 2023 | $33,741 | 14 | Novo Nordisk AS ($23,380) |
| 2022 | $16,225 | 8 | PFIZER INC. ($9,580) |
| 2021 | $5,460 | 7 | PFIZER INC. ($5,420) |
| 2020 | $18,560 | 10 | PFIZER INC. ($18,560) |
| 2019 | $18,645 | 18 | PFIZER INC. ($18,524) |
| 2018 | $31,080 | 16 | PFIZER INC. ($30,530) |
| 2017 | $7,738 | 8 | GlaxoSmithKline, LLC. ($6,700) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: Genetic Disease | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 07/20/2024 | Edwards Lifesciences Corporation | — | Food and Beverage | In-kind items and services | $186.48 | General |
| 05/27/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $12,981.25 | General |
| 05/27/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $10,879.55 | General |
| 05/27/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $871.08 | General |
| 05/27/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $263.38 | General |
| 05/27/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $196.80 | General |
| 04/16/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $4,935.00 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $35.68 | General |
| 11/23/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,148.00 | General |
| 10/09/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $203.00 | General |
| 10/09/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $119.97 | General |
| 09/06/2023 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: ARRY371797 CLINICAL PUBLICATION PROGRAM | ||||||
| 09/06/2023 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: ARRY371797 CLINICAL PUBLICATION PROGRAM | ||||||
| 07/06/2023 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: ARRY371797 CLINICAL PUBLICATION PROGRAM | ||||||
| 03/20/2023 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $161.61 | General |
| Category: Heart Failure and Hypertension | ||||||
| 03/13/2023 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $13,756.25 | General |
| Category: Cardiovascular | ||||||
| 03/13/2023 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $8,686.74 | General |
| Category: Cardiovascular | ||||||
| 03/13/2023 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $489.44 | General |
| Category: Cardiovascular | ||||||
| 03/13/2023 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $234.49 | General |
| Category: Cardiovascular | ||||||
| 03/13/2023 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $213.36 | General |
| Category: Cardiovascular | ||||||
| 03/05/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $58.13 | General |
| Category: Cardiovascular | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TAFAMIDIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $11,560 | 7 |
| PF07265803 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,770 | 5 |
| ARRY371797 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,340 | 3 |
| TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
| NO PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 224 | 350 | $113,202 | $31,622 |
| 2022 | 7 | 283 | 524 | $155,544 | $39,565 |
| 2021 | 11 | 405 | 724 | $218,383 | $57,213 |
| 2020 | 10 | 434 | 802 | $205,199 | $53,164 |
Total Patients
1,346
Total Services
2,400
Medicare Billing
$181,565
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 100 | 135 | $34,965 | $11,190 | 32.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 72 | $25,200 | $6,484 | 25.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 55 | $21,395 | $6,194 | 29.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $12,250 | $3,732 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 30 | $11,670 | $3,068 | 26.3% |
| 93750 | Evaluation of lower heart chamber assist device | Facility | 2023 | 11 | 33 | $7,722 | $953.92 | 12.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 124 | $43,400 | $9,317 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 76 | $18,844 | $6,785 | 36.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 40 | 48 | $17,587 | $5,084 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 50 | 63 | $15,645 | $4,469 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 36 | $13,164 | $4,368 | 33.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 72 | $16,560 | $3,737 | 22.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 17 | $8,840 | $2,486 | 28.1% |
| 93750 | Evaluation of lower heart chamber assist device | Facility | 2022 | 15 | 72 | $16,848 | $2,129 | 12.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 16 | 16 | $4,656 | $1,191 | 25.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 50 | 126 | $40,770 | $10,123 | 24.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 57 | 70 | $22,750 | $7,595 | 33.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 37 | 130 | $29,504 | $7,230 | 24.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 31 | 34 | $17,519 | $5,137 | 29.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 67 | 75 | $16,181 | $5,092 | 31.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 40 | 59 | $12,611 | $4,819 | 38.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 27 | 31 | $10,336 | $4,161 | 40.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 11 | 24 | $22,774 | $4,122 | 18.1% |
| 93750 | Evaluation of lower heart chamber assist device with physician analysis | Facility | 2021 | 26 | 115 | $26,910 | $3,501 | 13.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $5,184 | $1,735 | 33.5% |
About Dr. Daniel Judge, M.D
Dr. Daniel Judge, M.D is a Cardiovascular Disease healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790726917.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Judge, M.D has received a total of $165,251 in payments from pharmaceutical and medical device companies, with $33,801 received in 2024. These payments were reported across 93 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($85,100).
As a Medicare-enrolled provider, Judge has provided services to 1,346 Medicare beneficiaries, totaling 2,400 services with total Medicare billing of $181,565. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Advanced Heart Failure and Transplant Cardiology
- Location Charleston, SC
- Active Since 06/09/2006
- Last Updated 07/21/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1790726917
Products in Payments
- VYNDAQEL (Drug) $39,564
- AMVUTTRA (Drug) $2,820
- Barostim Neo System (Device) $161.61
- ONPATTRO (Drug) $121.58
- CAMZYOS (Drug) $58.13
- PRALUENT ALIROCUMAB INJECTION (Biological) $28.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Charleston
Robert Biederman, Md, MD
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jeffrey Winterfield, M.d, M.D
Cardiovascular Disease — Payments: $549,685
Cardiovascular Disease $549,685
Frank Cuoco, Md, MD
Cardiovascular Disease — Payments: $292,531
Cardiovascular Disease $292,531
Sarah Rinehart, Md, MD
Cardiovascular Disease — Payments: $198,204
Cardiovascular Disease $198,204
Dr. Sheldon Litwin, M.d, M.D
Cardiovascular Disease — Payments: $153,640
Cardiovascular Disease $153,640
Dr. Geetha Pinto, Md, MD
Cardiovascular Disease — Payments: $127,703
Cardiovascular Disease $127,703